Login to Your Account



Financings Roundup

Versartis' $25M Series C to Fund HGH Trial in Children

By Catherine Shaffer
Staff Writer

Wednesday, January 16, 2013
Versartis Inc., of Redwood City, Calif., closed a $25 million Series C financing round through Aisling Capital, Index Ventures, New Leaf Venture Partners and Advent Venture Partners to support clinical trials of VRS-317 for growth hormone deficiency in children.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription